Related Experiment Video

Updated: Mar 3, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.3K

The Servier oncology pipeline in 2017

Patrick Therasse1, Beatrice Perron1, Sarah A Novack2

  • 1Center for therapeutic innovation, Oncology Servier, Suresnes, France.

Future Oncology (London, England)
|April 22, 2017
PubMed

Insights

Servier focuses on developing novel cancer therapeutics targeting key molecular pathways. Future research will concentrate on apoptosis and immune components for treating solid and hematological tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Cancer is a complex disease requiring extensive research into its mechanisms and targeted therapies.
  • Servier, a pharmaceutical company, is dedicated to oncology research and development.
  • Current Servier treatments include non-Hodgkin's lymphoma and metastatic colorectal cancer.

Purpose of the Study:

  • To outline Servier's current oncology portfolio and future research directions.
  • To highlight Servier's commitment to innovative cancer treatment development.
  • To emphasize Servier's focus on apoptosis and immune system modulation in cancer therapy.

Main Methods:

  • Review of Servier's commercial oncology portfolio.
  • Analysis of Servier's ongoing oncology pipeline.
  • Identification of future research areas in cancer therapeutics.

Main Results:

  • Servier offers treatments for non-Hodgkin's lymphoma and metastatic colorectal cancer.
  • Servier's pipeline includes agents for solid and hematological tumors.
  • Future research will target apoptosis and immune components in cancer.

Conclusions:

  • Servier is committed to advancing oncology innovation through research and collaboration.
  • Servier prioritizes a patient-centered approach in developing novel cancer treatments.
  • Servier aims to develop cutting-edge therapeutics targeting critical cancer pathways.
Keywords:
apoptosisdrug developmentimmuno-oncologyoncologypixantronetrifluridine/tipiraciltyrosine kinase inhibitor

More Related Videos

Development of Compendium for Esophageal Squamous Cell Carcinoma03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

877
Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells10:03

Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells

Published on: July 5, 2019

9.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.2K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K